Doxycycline responding illnesses in returning travellers with undifferentiated non-malaria fever: a European multicentre prospective cohort study.


Journal

Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456

Informations de publication

Date de publication:
18 02 2023
Historique:
received: 05 05 2022
revised: 11 06 2022
accepted: 29 06 2022
pubmed: 7 8 2022
medline: 25 2 2023
entrez: 6 8 2022
Statut: ppublish

Résumé

Diagnosis of undifferentiated non-malaria fevers (NMF) in returning travellers is a great challenge. Currently, there is no consensus about the use of empirical antibiotics in returning travellers with undifferentiated NMF. Although studies in endemic areas showed that a wide range of pathogens implicated in undifferentiated NMF are treatable with doxycycline, the role of doxycycline in returning travellers with fever still has to be explored. Prospective European multicentre cohort study of febrile international travellers (November 2017-November 2019). Immunological and molecular diagnostic techniques for doxycycline responding illnesses (DRI) agents such as Anaplasma phagocytophilum, spotted fever group Rickettsia spp., typhus group Rickettsia spp., Coxiella burnetii, Bartonella spp., Orientia tsutsugamushi, Borrelia miyamotoi, Borrelia recurrentis and Leptospira spp. were systematically performed in all patients with undifferentiated NMF. We estimated the prevalence and predictive factors of DRI in returning travellers with undifferentiated NMF. Among 347 travellers with undifferentiated NMF, 106 (30·5%) were finally diagnosed with DRI. Only 57 (53·8%) of the 106 DRI infections were diagnosed by the standard of care. The main causes of DRI were: 55 (51·9%) Rickettsia spp., 16 (15·1%) C. burnetii; 15 (14·2%) Bartonella spp.; 13 (12·3%) Leptospira spp. and 10 (9·5%) A. phagocytophilum. The only predictive factor associated with DRI was presenting an eschar (aOR 39·52, 95%CI 4·85-322·18). Features of dengue such as retro-orbital pain (aOR 0·40, 95%CI 0·21-0·76) and neutropenia (aOR 0·41, 95%CI 0·21-0·79) were negatively associated with DRI. Although DRI are responsible for 30% of undifferentiated NMF cases in travellers, those are seldom recognized during the first clinical encounter. Empirical treatment with doxycycline should be considered in returning travellers with undifferentiated fever and negative tests for malaria and dengue, particularly when presenting severe illness, predictive factors for rickettsiosis or no features of dengue.

Sections du résumé

BACKGROUND
Diagnosis of undifferentiated non-malaria fevers (NMF) in returning travellers is a great challenge. Currently, there is no consensus about the use of empirical antibiotics in returning travellers with undifferentiated NMF. Although studies in endemic areas showed that a wide range of pathogens implicated in undifferentiated NMF are treatable with doxycycline, the role of doxycycline in returning travellers with fever still has to be explored.
METHODS
Prospective European multicentre cohort study of febrile international travellers (November 2017-November 2019). Immunological and molecular diagnostic techniques for doxycycline responding illnesses (DRI) agents such as Anaplasma phagocytophilum, spotted fever group Rickettsia spp., typhus group Rickettsia spp., Coxiella burnetii, Bartonella spp., Orientia tsutsugamushi, Borrelia miyamotoi, Borrelia recurrentis and Leptospira spp. were systematically performed in all patients with undifferentiated NMF. We estimated the prevalence and predictive factors of DRI in returning travellers with undifferentiated NMF.
RESULTS
Among 347 travellers with undifferentiated NMF, 106 (30·5%) were finally diagnosed with DRI. Only 57 (53·8%) of the 106 DRI infections were diagnosed by the standard of care. The main causes of DRI were: 55 (51·9%) Rickettsia spp., 16 (15·1%) C. burnetii; 15 (14·2%) Bartonella spp.; 13 (12·3%) Leptospira spp. and 10 (9·5%) A. phagocytophilum. The only predictive factor associated with DRI was presenting an eschar (aOR 39·52, 95%CI 4·85-322·18). Features of dengue such as retro-orbital pain (aOR 0·40, 95%CI 0·21-0·76) and neutropenia (aOR 0·41, 95%CI 0·21-0·79) were negatively associated with DRI.
CONCLUSIONS
Although DRI are responsible for 30% of undifferentiated NMF cases in travellers, those are seldom recognized during the first clinical encounter. Empirical treatment with doxycycline should be considered in returning travellers with undifferentiated fever and negative tests for malaria and dengue, particularly when presenting severe illness, predictive factors for rickettsiosis or no features of dengue.

Identifiants

pubmed: 35932455
pii: 6657742
doi: 10.1093/jtm/taac094
pii:
doi:

Substances chimiques

Doxycycline N12000U13O

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : International Society of Travel Medicine

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of International Society of Travel Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Daniel Camprubí-Ferrer (D)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

José Antonio Oteo (JA)

Center of Rickettsiosis and Arthropod-Borne Diseases, Hospital Universitario San Pedro-CIBIR, Logroño 26006, Spain.

Emmanuel Bottieau (E)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium.

Blaise Genton (B)

Swiss Tropical and Public Health Institute, Basel 4051, Switzerland.
Center for Primary Care and Public Health, University of Lausanne, 1011, Switzerland.

Leire Balerdi-Sarasola (L)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Aránzazu Portillo (A)

Center of Rickettsiosis and Arthropod-Borne Diseases, Hospital Universitario San Pedro-CIBIR, Logroño 26006, Spain.

Ludovico Cobuccio (L)

Swiss Tropical and Public Health Institute, Basel 4051, Switzerland.
Center for Primary Care and Public Health, University of Lausanne, 1011, Switzerland.

Steven Van Den Broucke (S)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium.

Sonia Santibáñez (S)

Center of Rickettsiosis and Arthropod-Borne Diseases, Hospital Universitario San Pedro-CIBIR, Logroño 26006, Spain.

Dániel Cadar (D)

Bernhard Nocht Institute for Tropical Medicine, National Reference Centre for Tropical Pathogens, Hamburg 20359, Germany.

Natalia Rodriguez-Valero (N)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Alex Almuedo-Riera (A)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Carme Subirà (C)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Valérie d'Acremont (V)

Swiss Tropical and Public Health Institute, Basel 4051, Switzerland.
Center for Primary Care and Public Health, University of Lausanne, 1011, Switzerland.

Miguel J Martinez (MJ)

Microbiology Department, Hospital Clínic Barcelona, 08036, Spain.

Montserrat Roldán (M)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Jessica Navero-Castillejos (J)

Microbiology Department, Hospital Clínic Barcelona, 08036, Spain.

Marjan Van Esbroeck (M)

Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium.

Jose Muñoz (J)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona 08036, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH